Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

NewsGuard 100/100 Score
Sep 22 2010

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

Teva previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven Orange Book patents, covering the chemical composition of COPAXONE®, pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , , ,

Comments (0)

Suggested Reading

Recycled food waste may be contaminated with pharmaceutical residues, research reveals
Lancet Commission predicts sharp increase in global prostate cancer cases
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Study highlights global fertility decline and its implications for the future
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
LabVantage celebrates customer success with record number of software deployments in FY 2024
Supply chain assessment and management, optimizing pharmaceutical supply chains
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk